Neurocrine Biosciences Inc. (NBIX)

101.18
0.32 0.32
NASDAQ : Health Technology
Prev Close 101.50
Open 102.08
Day Low/High 100.88 / 102.50
52 Wk Low/High 64.72 / 125.59
Volume 176.72K
Avg Volume 654.20K
Exchange NASDAQ
Shares Outstanding 91.58M
Market Cap 9.26B
EPS 0.20
P/E Ratio 505.60
Div & Yield N.A. (N.A)
Neurocrine Biosciences To Present Data On INGREZZA® (valbenazine) For Tardive Dyskinesia; Opicapone And VY-AADC For Parkinson's Disease, At The 2019 International Congress Of Parkinson's Disease And Movement Disorders®

Neurocrine Biosciences To Present Data On INGREZZA® (valbenazine) For Tardive Dyskinesia; Opicapone And VY-AADC For Parkinson's Disease, At The 2019 International Congress Of Parkinson's Disease And Movement Disorders®

- Phase III Data Analyses Evaluate the Long-Term Benefit of INGREZZA® (valbenazine) 40 mg and Early Response to Treatment in Patients with Tardive Dyskinesia

Neurocrine Biosciences Announces Appointment Of Leslie V. Norwalk To Board Of Directors

Neurocrine Biosciences Announces Appointment Of Leslie V. Norwalk To Board Of Directors

SAN DIEGO, Sept. 11, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc.

Neurocrine Biosciences To Present At Upcoming Healthcare Conferences

Neurocrine Biosciences To Present At Upcoming Healthcare Conferences

SAN DIEGO, Aug. 28, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc.

Otezla Price Under Microscope -- but Look Closely and It Checks Out

Otezla Price Under Microscope -- but Look Closely and It Checks Out

Sure, Celgene, in its tie-up with Bristol-Myers Squibb, had to sell to meet merger requirements, but look at the future pay off for Amgen.

AbbVie Submits New Drug Application To US FDA For Investigational Elagolix For Management Of Heavy Menstrual Bleeding Associated With Uterine Fibroids In Women

AbbVie Submits New Drug Application To US FDA For Investigational Elagolix For Management Of Heavy Menstrual Bleeding Associated With Uterine Fibroids In Women

- New Drug Application (NDA) is supported by data from pivotal Phase 3 studies of nearly 800 patients

Neurocrine Biosciences Reports Second Quarter 2019 Financial Results

Neurocrine Biosciences Reports Second Quarter 2019 Financial Results

INGREZZA® (valbenazine) Second Quarter Net Product Sales of $180.5 Million with Approximately 31,600 TRx

Neurocrine Biosciences Announces FDA Acceptance Of New Drug Application For Opicapone As An Adjunctive Treatment For Patients With Parkinson's Disease

Neurocrine Biosciences Announces FDA Acceptance Of New Drug Application For Opicapone As An Adjunctive Treatment For Patients With Parkinson's Disease

- FDA Accepts New Drug Application for Opicapone, a Once-Daily, Oral, Catechol-O-Methyltransferase (COMT) Inhibitor, as Adjunctive Therapy to Levodopa/Carbidopa

Neurocrine Biosciences Announces Conference Call And Webcast Of Second Quarter 2019 Financial Results

Neurocrine Biosciences Announces Conference Call And Webcast Of Second Quarter 2019 Financial Results

Conference Call and Webcast Scheduled for Monday, July 29

Neurocrine Biosciences To Present Data On INGREZZA® (valbenazine) And Opicapone At The 2019 World Congress On Parkinson's Disease And Related Disorders

Neurocrine Biosciences To Present Data On INGREZZA® (valbenazine) And Opicapone At The 2019 World Congress On Parkinson's Disease And Related Disorders

- INGREZZA Data from Long-Term Phase III Studies Support Sustained Clinical Benefit, Safety and Tolerability in Patients with Tardive Dyskinesia

Neurocrine Biosciences To Present At Goldman Sachs 40th Annual Global Healthcare Conference

Neurocrine Biosciences To Present At Goldman Sachs 40th Annual Global Healthcare Conference

Live Audio Webcast will be on June 11, 2019

Neurocrine Biosciences To Present At Jefferies 2019 Global Healthcare Conference

Neurocrine Biosciences To Present At Jefferies 2019 Global Healthcare Conference

Live Audio Webcast will be on June 6, 2019

Neurocrine Biosciences Presents New Data From RE-KINECT, The Largest Real-World Screening Study Of Possible Tardive Dyskinesia, Demonstrating The Effect Of Involuntary Movements On Patient Quality Of Life

Neurocrine Biosciences Presents New Data From RE-KINECT, The Largest Real-World Screening Study Of Possible Tardive Dyskinesia, Demonstrating The Effect Of Involuntary Movements On Patient Quality Of Life

- Nearly 30% of Patients with Possible Tardive Dyskinesia Reported Moderate-to-Extreme Problems Performing Their Usual Activities, Including Work, Housework and Leisure Activities

Neurocrine Biosciences To Present New Quality-of-Life Data Analysis From RE-KINECT, The Largest Real-World Screening Study Of Possible Tardive Dyskinesia Patients, At The 2019 American Psychiatric Association Annual Meeting

Neurocrine Biosciences To Present New Quality-of-Life Data Analysis From RE-KINECT, The Largest Real-World Screening Study Of Possible Tardive Dyskinesia Patients, At The 2019 American Psychiatric Association Annual Meeting

- RE-KINECT Analysis Provides Insight into the Impact of Possible Tardive Dyskinesia on Patient Health-Related Quality of Life

Neurocrine Biosciences To Present At Bank Of America Merrill Lynch Health Care Conference 2019

Neurocrine Biosciences To Present At Bank Of America Merrill Lynch Health Care Conference 2019

Live Audio Webcast will be on May 14, 2019

Neurocrine Biosciences Honors Mental Health Month And Raises Awareness Of Tardive Dyskinesia And Its Impact On Patients

Neurocrine Biosciences Honors Mental Health Month And Raises Awareness Of Tardive Dyskinesia And Its Impact On Patients

- Mental Health Advocacy Community Recognizes and 25 States Declare Tardive Dyskinesia Awareness Week as Part of Mental Health Month to Raise Prominence of Tardive Dyskinesia and Highlight the Impact on the Lives of Patients

Neurocrine Biosciences And Voyager Therapeutics Announce Phase I Results For VY-AADC In Patients With Parkinson's Disease At The American Academy Of Neurology Annual Meeting

Neurocrine Biosciences And Voyager Therapeutics Announce Phase I Results For VY-AADC In Patients With Parkinson's Disease At The American Academy Of Neurology Annual Meeting

- Results Confirm the Posterior Trajectory as an Additional Surgical Delivery Route for VY-AADC in Patients with Parkinson's Disease

Neurocrine Biosciences To Present Data Analyses On INGREZZA® (valbenazine) And Opicapone At The 2019 American Academy Of Neurology Annual Meeting

Neurocrine Biosciences To Present Data Analyses On INGREZZA® (valbenazine) And Opicapone At The 2019 American Academy Of Neurology Annual Meeting

- Long-Term Data from Two Phase III Trials Show INGREZZA Sustained Improvement in Tardive Dyskinesia Symptoms in Patients Taking Concomitant Medications for Psychiatric Disorders

Neurocrine Biosciences Reports First Quarter 2019 Financial Results

Neurocrine Biosciences Reports First Quarter 2019 Financial Results

INGREZZA® (valbenazine) First Quarter Net Product Sales of $136.4 Million with Approximately 24,200 TRx

Neurocrine Biosciences Announces Conference Call And Webcast Of First Quarter 2019 Financial Results

Neurocrine Biosciences Announces Conference Call And Webcast Of First Quarter 2019 Financial Results

Conference Call and Webcast Scheduled for Monday, April 29

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AJRD, BXP, CARB, CDR, DOC, FTAI, GHDX, GOV, HOME, IKNX, LOCO, NBIX, NYLD.A, RFP, UEIC Downgrades: APU, HY, MFNC, SGMS, TFX Initiations: EEX, SSTI Read on to get TheStreet Quant Ratings' detailed report:

3 'Strong Buy' Healthcare Stocks Poised to Surge

3 'Strong Buy' Healthcare Stocks Poised to Surge

Here are the top healthcare bets ticking all the boxes for analysts.

5 Stocks That Are Screaming Buys Right Now

5 Stocks That Are Screaming Buys Right Now

Stay active and selective: These are the five best stocks to invest in right now

Spring Cleaning: Let's Tidy Up Some Trades

Spring Cleaning: Let's Tidy Up Some Trades

Not every trade can be a winner, so let's lighten the load here.

A Bullish Play on Neurocrine Biosciences

A Bullish Play on Neurocrine Biosciences

Analysts weren't shy to defend the company after Tuesday's earnings.

Tuesday Investor Blog: Is the Bull Market in Stocks Being Ripped to Shreds?

Tuesday Investor Blog: Is the Bull Market in Stocks Being Ripped to Shreds?

Bring your A-game in these markets or go home. Just keeping it real. Here is what you need to know on Tuesday.

15 Biotech Firms That Have Strong Potential to Be Acquired: Jefferies

15 Biotech Firms That Have Strong Potential to Be Acquired: Jefferies

'Balance sheets are flush with cash and there is a need to grow for large health care companies,' Jefferies analysts wrote.

Watch These Biotechs and the FDA Calendar

Watch These Biotechs and the FDA Calendar

Here are a few key events I will be watching closely for in the months ahead on stocks I think are buys at current levels.

3 Key Biotech Catalysts on the FDA Calendar

3 Key Biotech Catalysts on the FDA Calendar

A roundup of biotech names with actions pending at the FDA in coming weeks.

Who Benefits From Tax Reform?

Who Benefits From Tax Reform?

Technology and biotech companies seem to be among the big winners.

TheStreet Quant Rating: C+ (Hold)